Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ФГБНУ «Научный центр психического здоровья». 115522, Россия, Москва, Каширское ш., 34; 2ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1 i.oleichik@mail.ru
Список исп. литературыСкрыть список 1. Lu Y, Mallinckrodt C, Goldstein DJ et al. Возможности терапии депрессии с помощью дулоксетина (расширенный реферат). Психиатрия и психофармакотерапия. 2006; 8 (3): 53–60. / Lu Y, Mallinckrodt C, Goldstein DJ et al. Vozmozhnosti terapii depressii s pomoshch'iu duloksetina (rasshirennyi referat). Psychiatry and Psychopharmacotherapy. 2006; 8 (3): 53–60. [in Russian] 2. Ilyas S, Moncrieff J. Trends in prescriptions and costs of drugs for mental disorders in England, 1998–2010. Br J Psychiatry 2012; 200 (5): 393–8. 3. Kimayer LJ, Robbins JM, Dworkind M, Yaffe MJ. Somatization and the recognition of depression and anxiety in primary care. Am Psychiatry 1993; 150: 734–41. 4. Kurian BT, Greer TL, Trivedi MH. Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms. Expert Rev Neurother 2009; 9 (7): 975–84. 5. Воробьева О.В. Депрессия в пожилом возрасте. Consilium Medicum. 2007; 9 (12): 24–8. / Vorob'eva O.V. Depressiia v pozhilom vozraste. Consilium Medicum. 2007; 9 (12): 24–8. [in Russian] 6. Олейчик И.В., Копейко Г.И. Эффективность и безопасность монотерапии антидепрессантами эндогенных юношеских депрессий. Рос. психиатрич. журн. 2011; 1: 62–8. / Oleichik I.V., Kopeiko G.I. Effektivnost' i bezopasnost' monoterapii antidepressantami endogennykh iunosheskikh depressii. Ros. psikhiatrich. zhurn. 2011; 1: 62–8. [in Russian] 7. Иванов М.В., Мазо Г.Э., Чомский А.Н. К проблеме антидепрессантов «первого выбора» при терапии депрессивного расстройства. Психиатрия и психофармакотерапия им. П.Б.Ганнушкина. 2009; 5: 6–8. / Ivanov M.V., Mazo G.E., Chomskii A.N. K probleme antidepressantov "pervogo vybora" pri terapii depressivnogo rasstroistva. Psikhiatriia i psikhofarmakoterapiia im. P.B.Gannushkina. 2009; 5: 6–8. [in Russian] 8. Deecher DC, Beyer CE, Johnston G, Bray G et al. Desvenlafaxine Succinate: a new serotonin and norepinephrine reuptake inhibitor. JPET 2006; 318: 657–65. 9. Вертоградова О.П., Моисейчева О.В. Особенности динамики депрессии при лечении симбалтой. Соц. и клин. психиатрия. 2009; 19 (4). ). / Vertogradova O.P., Moiseicheva O.V. Osobennosti dinamiki depressii pri lechenii simbaltoi. Sots. i klin. psikhiatriia. 2009; 19 (4). [in Russian] 10. Brecht S, Desaiah D, Marechal ES et al. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial. J Clin Psychiatry 2011; 72 (8): 1086–94. 11. Oakes TM, Myers AL, Marangell LB et al. Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol. Hum Psychopharmacol 2012; 27 (1): 47–56. 12. Дробижев М.Ю. Дулоксетин: новый антидепрессант и традиционная система координат (эффективность, терапевтический спектр, безопасность и переносимость). Психиатрия и психофармакотерапия им. П.Б.Ганнушкина. 2005; 2: 84–5. / Drobizhev M.Iu. Duloksetin: novyi antidepressant i traditsionnaia sistema koordinat (effektivnost', terapevticheskii spektr, bezopasnost' i perenosimost'). Psikhiatriia i psikhofarmakoterapiia im. P.B.Gannushkina. 2005; 2: 84–5. [in Russian] 13. Russell JM, Weisberg R, Fava M, Hartford JT. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms. Depress Anxiety 2008; 25 (7): 1–11. 14. Zhang Y, Huang G, Yang S et al. Duloxetine in treating generalized anxiety disorder in adults: A meta-analysis of published randomized, double-blind, placebo-controlled trials. Asia Pac Psychiatry 2016; 8 (3): 215–25. 15. Huang J, Wang Y, Chen J, Zhang Y. Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline. Neuropsychiatr Dis Treat 2018; 14: 2473–84. 16. Kuga A, Tsuji T, Hayashi S, Fujikoshi S. An observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of life. Neuropsychiatr Dis Treat 2017; 13: 2115–24. 17. Li G, Wang X, Ma D. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials. Clin Drug Investig 2016; 36 (7): 509–17. 18. Minami K, Tamano R, Kasai E et al. Effects of duloxetine on pain and walking distance in neuropathic pain models via modulation of the spinal monoamine system. Eur J Pain 2018; 22 (2): 355–69. 19. Raskin J, Wiltse CG, Siegal A et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007; 164 (6): 900–9. 20. Artemenko AR, Kurenkov AL, Nikitin SS, Filatova EG. Duloxetine in the treatment of chronic migraine, Zh Nevrol Psikhiatr Im S.S.Korsakova 2010; 110 (1): 49–54. 21. Дюкова Г.М., Погромов А.П, Леонова М.Л. Функциональные заболевания желудочно-кишечного тракта: эффективность терапии дулоксетином. Неврология и ревматология. 2010; 1: 43–7. / Diukova G.M., Pogromov A.P, Leonova M.L. Funktsional'nye zabolevaniia zheludochno-kishechnogo trakta: effektivnost' terapii duloksetinom. Nevrologiia i revmatologiia. 2010; 1: 43–7. [in Russian] 22. Marangell LB, Clauw DJ, Choy E, Wang F. Comparative pain and mood effects in patients with comorbid fibromyalgia and major depressive disorder: secondary analyses of four pooled randomized controlled trials of duloxetine. Pain 2011; 152 (1): 31–7. 23. Norton PA et al. Duloxetine versus placebo in the treatment of stress urinary incontinence. American journal of obstetrics and gynecology 2002; 187 (1): 40–8. 24. Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Neuropsychopharmacol 2004; 14 (6): 457–70. 25. Wernicke J, Liedo A, Raskin J et al. An evaluation of the caprofile of duloxetine. Drug Saf 2007; 30 (5): 437–55. 26. Framplon JE, Plosker GL. Duloxetine. A review of its use in the treatment of major depressive disorder. CNS Drugs 2007; 21 (7): 581–609. 27. Emslie GJ, Wells TG, Prakash A et al. Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 2015; 25 (4): 293–305. 28. Emslie GJ, Prakash A, Zhang Q et al. A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 2014; 24 (4): 170–9. 29. Delgado PL, Brannan SK, Mallinckrodt CH, Tran PV. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 2005; 66 (6): 686–92. 30. Knadler MP, Lobo E, Chappell J et al. Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet 2011; 50: 281–94. 31. Radovanuvic M, Pisljar M, Babric-Zagar B et al. Efficaсy end safety of duloxetine in the treatment of depression, generalized anxiety disorder and diabetic peripheral neuropathic pain. Viceversa 2017; 63: 60–72. 32. Pišljar M. Epidemiološka raziskava uporabe duloksetina pri slovenskih bolnikih z veliko depresivno motnjo, generalizirano anksiozno motnjo ali bolečino diabetične periferne nevropatije. KEPSU 08/2015 – DULSEVIA/SI. Zaključno poročilo. Podatki iz dokumentacije Krka, d. d., Novo mesto. 2017.